Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges

Table 8 Level of evidence of the common pharmacological and biomedical interventions in pediatric autism spectrum disorder

Intervention type	Mechanism of action	Evidence level	Recommended dose (pediatric)	Common side effects	Key clinical notes
Antipsychotics
Risperidone	Antagonist of D2 (dopamine) and serotonin 2A receptors	High (FDA-approved for irritability)[1]	Initial: 0.25-0.5 mg/day. Target: 0.5-3.0 mg/day (weight-based)[2]	Weight gain, increased appetite, sedation, hyperprolactinemia, enuresis, tremor[3]	Most effective for irritability/aggression. Requires monitoring of weight, metabolic profile, and prolactin[4]
Aripiprazole	Partial agonist of D2 and serotonin 1A; antagonist of serotonin 2A	High (FDA-approved for irritability)[5]	Initial: 2 mg/day. Target: 5-15 mg/day[6]	Sedation, vomiting, tremor, akathisia, weight gain (less than risperidone)[7]	Metabolic profile generally better than risperidone. Can lower prolactin levels[8]
Psychostimulants
Methylphenidate	Blocks reuptake of norepinephrine and dopamine	Moderate[9]	Start low (e.g., 2.5-5 mg/day) and titrate. Max 2 approximately mg/kg/day or 60 mg/day[10]	Appetite suppression, insomnia, irritability, emotional lability[11]	Effective for ADHD symptoms but less tolerated in ASD than in pure ADHD. “Irritability” is a dose-limiting side effect[12]
Non-stimulants
Atomoxetine	Selective norepinephrine reuptake inhibitor	Moderate[13]	0.5 mg/kg/day to 1.2-1.4 mg/kg/day[14]	Nausea, fatigue, decreased appetite, early morning awakening[15]	Good alternative if stimulants aren’t tolerated. Effects may take weeks to appear[16]
Alpha-2 agonists
Guanfacine	Selective alpha-2A adrenergic receptor agonist	Moderate (RCTs available)[17]	1-4 mg/day (extended release)[18]	Drowsiness, fatigue, hypotension, dry mouth[19]	Effective for hyperactivity and impulsivity. Monitor BP and pulse[20]
Clonidine	Non-selective alpha-2 adrenergic agonist	Low/moderate (small RCTs)[21]	Oral/transdermal. Approximately 0.1-0.2 mg/day (titrated)[22]	Sedation (prominent), dizziness, hypotension, irritability[23]	Useful for hyperarousal and sleep. More sedating than guanfacine[24]
Mood stabilizers
Valproate	Increases GABA; blocks Na+ channels; epigenetic modulation	Low/moderate (mixed RCTs)[25]	Titrated to serum levels (50-100 μg/mL)[26]	Weight gain, GI upset, tremor, hair loss, thrombocytopenia, hepatotoxicity (rare)[27]	May reduce irritability/aggression. Avoid in metabolic disorders (mitochondrial)[28]
CBD	Modulates endocannabinoid system (low affinity CB1/CB2)	Low/emerging (one positive RCT)[29]	Variable. e.g., 20:1 CBD:THC oil or pure CBD[30]	Somnolence, decreased appetite, restlessness, diarrhea[31]	Shows promise for severe behavioral problems. Long-term safety data in kids is limited[32]
SSRI/antidepressants
Fluoxetine	SSRI	Low/negative for core symptoms[33]	Low dose start (e.g., 2.5-5 mg)[34]	Behavioral activation (hyperactivity, agitation), insomnia, GI upset[35]	Not effective for core RRBs in large trials. Use for comorbid anxiety/depression[36]
Sertraline	SSRI	Low/negative for core symptoms[37]	Low dose start (e.g., 25 mg)[38]	Hyperactivity, insomnia, GI disturbance[39]	May benefit a subgroup with specific genetic profile (solute carrier family 6 member 4 long/Long genotype)[40]
Metabolic/dietary
Methyl B12	Cofactor for methionine synthase; supports methylation	Low (small RCTs)[41]	64.5-75 μg/kg subcutaneous injection every 3 days[42]	Generally safe. Hyperactivity/agitation possible. Cobalt accumulation[43]	May improve clinical global impression in some children[44]
Folinic Acid	Reduced folate; supports methylation/DNA synthesis	Low/moderate (one positive RCT)[45]	High dose (up to 2 mg/kg/day; max 50 mg)[46]	Excitement, insomnia, aggression (rare)[47]	Improved verbal communication in FRAA-positive children[48]
L-Carnitine	Transports fatty acids for mitochondrial oxidation	Low (small/pilot studies)[49]	50-100 mg/kg/day (up to 400 mg/kg used in pilots)[50]	Fishy body odor, diarrhea/GI upset[51]	May help a subset with mitochondrial dysfunction. Odor is a limiting side effect[52]
Sulforaphane	Upregulates antioxidant response (Nrf2 pathway)	Low/moderate (mixed RCTs)[53]	Derived from broccoli sprout extract (variable potency)[54]	GI upset, insomnia, smell/taste aversion[55]	showed benefit in young adults; results in children are mixed[56]
Gut-brain axis
Probiotics	Modulate gut microbiota and gut-brain signaling	Low/moderate (mixed)[57]	Strain-dependent (e.g., Lactobacillus plantarum, Lactobacillus reuteri)[58]	GI bloating, gas (usually mild)[59]	Some strains improve GI symptoms and potentially some behavioral symptoms (anxiety)[60]
Fecal Transplant (FMT)	Restores diverse/healthy gut microbiota	Low/emerging (open label/small RCTs)[61]	Oral capsules or rectal enema (experimental protocols)[62]	GI symptoms (diarrhea, pain), fever (transient)[63]	Promising long-term data on GI and core symptoms in small cohorts. Investigational[64]
Experimental
Bumetanide	Diuretic; reduces intracellular chloride (restores GABA inhibition)	Low/controversial (failed phase 3)[65]	0.5-1.0 mg twice daily[66]	Hypokalemia (frequent), diuresis, dehydration[67]	Phase 3 trials terminated for futility. May benefit specific biological subgroups[68]
Oxytocin	Neuropeptide; enhances social cognition/bonding	Low/negative (large RCT negative)[69]	Intranasal spray (various doses, e.g., 24 IU)[70]	Nasal irritation, epistaxis[71]	Large trial showed no benefit over placebo[72]
Immunotherapy (IVIG)	Modulates immune system; neutralizes autoantibodies	Very low (case series/uncontrolled)[73]	Intravenous (hospital based)[74]	Headache, fever, aseptic meningitis, risk of infection/thrombosis[75]	Reserved for rare cases with identifiable autoimmune encephalitis/markers[76]

FDA: Food and Drug Administration; ADHD: Attention-deficit/hyperactivity disorder; ASD: Autism spectrum disorder, RCT: Randomized controlled trial; GABA: Gamma-aminobutyric acid; BP: Blood pressure; GI: Gastrointestinal; CBD: Cannabidiol; THC: Tetrahydrocannabinol; SSRI: Selective serotonin reuptake inhibitor; RRBs: Restricted and repetitive behaviors; FRAA: Folate receptor-α autoantibodies; Nrf2: Nuclear factor erythroid 2-related factor 2; FMT: Fecal microbiota transplantation.